>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

CompanyHeadlineTime (ET)
ORCLIs Oracle's 29% crash the best AI bargain on Wall Street right now?04/13 02:06
BKRBaker Hughes Announces Sale of Waygate Technologies to Hexagon04/13 02:00
PLCOSB GROUP PLC - Transaction in Own Shares04/13 02:00
NPACYFPT and Quadient Reinforce Long-Standing Strategic Partnership to Bolster Digital Transformation and Co-Innovation04/13 02:00
GMCirrus Aircraft: The Only Pure-Play General Aviation Stock Is A Strong Buy04/13 01:56
TSCDYFTSE 100 shares to watch this week: Tesco, Rolls-Royce, IAG, Shell, BP04/13 01:52
IOOFFInsignia Financial Ltd. (IOOFF) Shareholder/Analyst Call Transcript04/13 01:41
PNCPNC Financial Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts04/13 01:35
NAVNNavan, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NAVN04/13 01:19
METAPhilippines Orders Meta to Tighten Measures Against ‘Panic-Inducing' Fake News04/13 01:18
NAVNNAVN Investors Have Opportunity to Lead Navan, Inc. Securities Fraud Lawsuit with the Schall Law Firm04/13 01:17
PYPLPayPal Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PYPL04/13 01:16
CORTCorcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT04/13 01:16
BNOFrom panic to pricing in: Are markets past 'peak fear and sell-off' despite oil price surge?04/13 01:14
BNOWhy pressure is mounting at oil giant BP ahead of its annual general meeting04/13 01:00
RHHBYRoche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis04/13 01:00
SNYPress Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria04/13 01:00
WKEYWISeSat and Swiss Space Command of the Swiss Armed Forces Complete Pilot Phase and Prepare Next-Generation WISeSat 6U Mission Planned for November 202604/13 01:00
CSUDupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)04/13 01:00
GMHLFGAM Holding AG announces proposed Board of Directors for election at 2026 Annual General Meeting04/13 01:00

Market News ×
Loading news…